Boris Peaker
Stock Analyst at TD Cowen
(2.01)
# 3,077
Out of 5,012 analysts
19
Total ratings
36.36%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Downgrades: Hold | n/a | $1.72 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $51.84 | +92.90% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $4.31 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $23.62 | +111.69% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $41.87 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $12.03 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $9.92 | +192.34% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $3.33 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $58.00 | - | 1 | Mar 15, 2022 | |
| NCNA NuCana | Downgrades: Market Perform | n/a | $7.02 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $49.22 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $797.35 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $87.61 | +16.43% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.97 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.84 | - | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.96 | - | 1 | Jul 24, 2017 |
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.72
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $51.84
Upside: +92.90%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.31
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $23.62
Upside: +111.69%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $41.87
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.03
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $9.92
Upside: +192.34%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.33
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $58.00
Upside: -
NuCana
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $7.02
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $49.22
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $797.35
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $87.61
Upside: +16.43%
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.97
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $0.84
Upside: -
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $7.96
Upside: -